Prestige Consumer Healthcare (PBH) Earnings: Q2 Fiscal 2027 Results and Next Report Date

The quarter ended September 30, 2026 and Prestige Consumer Healthcare published the results on November 5, 2026. Revenue and diluted EPS are shown against Q2 fiscal 2026, the same quarter a year earlier, which takes seasonal swings out of the comparison. Prestige Consumer Healthcare reports EPS two ways: GAAP, under the accounting rules every US filer follows, and Adjusted Diluted EPS, which leaves out items the company considers outside its operating results. The release reconciles the two, and when they diverge, the reconciliation says why.

• Q2 fiscal 2027 includes $65.1 million of revenue from the Breathe Right portfolio (acquired June 12, 2026) and LaCorium Health (acquired July 1, 2026). Excluding those and foreign currency, revenue fell 1.6%.
• Prestige's fiscal year ends March 31, so Q2 fiscal 2027 is the three months to September 30, 2026. With the Breathe Right deal it created a Wellness, Sleep & Other category and reclassified some brands among categories.

Source: Prestige Consumer Healthcare Q2 fiscal 2027 results, November 5, 2026. Also in the Form 10-Q for the quarter ended September 30, 2026. Figures as reported; checked against the release on November 10, 2026.

How Prestige Consumer Healthcare splits revenue in its own release, under its own labels, for Q2 fiscal 2027 against Q2 fiscal 2026. Indented lines are parts of the line above them.

• Prestige Consumer Healthcare's North American OTC Healthcare revenue was $272 million in Q2 fiscal 2027, up 18% from $231 million in Q2 fiscal 2026, 81% of total revenue.
• Prestige Consumer Healthcare's International OTC Healthcare revenue was $64.5 million in Q2 fiscal 2027, up 49% from $43.4 million in Q2 fiscal 2026, 19% of total revenue.

Segment lines are the figures writers cite most often, because they show where the growth in a quarter came from. Companies redraw their segments from time to time and restate the prior year to match, so a year-ago figure here can differ from the one printed a year ago. When that has happened, the note above says so.

From the earnings release

In its Q2 fiscal 2027 release, Prestige Consumer Healthcare said:

“Adjusting guidance outlook range to $1,280 to $1,290 million in revenue, $4.48 to $4.55 in Adjusted Diluted EPS”

“We are updating our fiscal 2027 outlook for revenues to $1,280 million to $1,290 million and adjusted diluted EPS of $4.48 to $4.55 primarily to reflect recent variability in Clear Eyes® production at Pillar5, which is expected to reduce product availability and revenue in the second half.”

“our medium-term outlook for approximately 10% annual revenue growth, approximately 8% annual EPS growth, and nearly $900 million of aggregate free cash flow over the next three years”

Source: Prestige Consumer Healthcare Q2 FY27 release, Nov 5, 2026.

This is the company's own guidance as of Nov 5, 2026, quoted as given. Walnut does not make forecasts of its own. Analyst estimates for the coming quarters are on the PBH forecast page.

Revenue and diluted EPS for the last 5 quarters. Each date links to that quarter's release.

GAAP total revenues and diluted EPS, each as first reported in that quarter's release.

Prestige Consumer Healthcare's next report is expected around February 4, 2027, a date estimated from its reporting history that the company has not yet confirmed. This page will show Q2 fiscal 2027 until those results are out and have been checked against the release.

Each quarter keeps its own page with the figures as reported, so a link to one stays pointed at the same numbers after the next report.

• Q2 fiscal 2027 (this page), reported Nov 5, 2026

Prestige Consumer Healthcare sells over-the-counter health brands such as Breathe Right, Monistat, Dramamine, Fleet, Hydralyte and Clear Eyes, in two segments. In Q2 fiscal 2027 North American OTC Healthcare brought in $271.8 million of the $336.3 million total, up 17.8%, and International OTC Healthcare $64.5 million, up 48.7%. Total revenue rose 22.7%, but fell 1.6% excluding foreign currency and a $65.1 million contribution from acquisitions. (Prestige Consumer Healthcare Q2 FY27 release, Nov 5, 2026)

The acquisitions are recent and large. On June 12, 2026 Prestige bought Breathe Right and other brands (the OTC Wellness Business) from Foundation Consumer Brands for $1,044.9 million in cash, funded by a new term loan, and on July 1, 2026 it bought Australia's LaCorium Health for $152.1 million. They added $47.5 million to North American revenue and $17.6 million to International. The new Wellness, Sleep & Other category brought in $47.3 million, against $6.4 million a year earlier. (Prestige Consumer Healthcare Q2 FY27 release, Nov 5, 2026; Prestige Consumer Healthcare Form 10-Q, Q2 FY27, Nov 5, 2026)

By category, Gastrointestinal was the largest at $63.1 million and Women's Health next at $53.6 million; Dermatologicals brought in $43.9 million, Cough, Cold & Allergy $36.3 million and Eye & Ear Care $34.6 million. Prestige put the organic decline down to order timing pulled into Q1 and a decline in Clear Eyes, whose supply from the Pillar5 plant it acquired on December 18, 2025 for $109.9 million remains limited. (Prestige Consumer Healthcare Form 10-Q, Q2 FY27, Nov 5, 2026; Prestige Consumer Healthcare Q2 FY27 release, Nov 5, 2026)

Sales are concentrated by retailer and brand. Walmart accounted for about 20% of gross revenues in the quarter and Amazon about 12%, and Prestige's five top-selling brands made up about 38%. (Prestige Consumer Healthcare Form 10-Q, Q2 FY27, Nov 5, 2026)

Prestige Consumer Healthcare's GAAP diluted EPS fell to $0.53 in Q2 fiscal 2027 from $0.86, while Adjusted Diluted EPS rose to $1.13 from $1.07. The adjustments added back $0.30 per share of inventory fair value step-up amortization from the acquisitions, $0.15 of Pillar5 remediation, overhead and idle capacity costs, $0.03 for a loss on extinguishment of debt and $0.02 of acquisition costs, less $0.12 of tax impact, plus a $0.22 normalized tax rate adjustment. (Prestige Consumer Healthcare Q2 FY27 release, Nov 5, 2026)

Financing the deals raised interest expense to $30.0 million from $10.0 million, and long-term debt stood at $2,079.3 million at September 30, 2026 against $994.0 million at March 31. The effective tax rate rose to 46.7% from 38.9%, mainly because Prestige established a valuation allowance against deferred tax assets. (Prestige Consumer Healthcare Q2 FY27 release, Nov 5, 2026; Prestige Consumer Healthcare Form 10-Q, Q2 FY27, Nov 5, 2026)

Diluted shares fell to 47.6 million from 49.3 million. In July 2026 Prestige issued $400 million of 6.25% senior notes due July 2034 to replace notes previously due in fiscal 2028, and put net debt at about $2 billion. (Prestige Consumer Healthcare Q2 FY27 release, Nov 5, 2026)

Diluted EPS divides net income by the weighted average number of shares outstanding in the quarter, plus the shares that options and other equity awards could add. Buybacks shrink that count and lift EPS for the same profit; share issuance and stock awards enlarge it.

Prestige Consumer Healthcare gives full-year guidance in its release. It cut its fiscal 2027 outlook to revenue of $1,280 million to $1,290 million, from $1,290 million to $1,315 million, and Adjusted Diluted EPS of $4.48 to $4.55, from $4.55 to $4.65. Organic revenue growth is now about flat, against +1.0% to +3.0% before, and adjusted free cash flow $265 million or more, against $270 million or more. (Prestige Consumer Healthcare Q2 FY27 release, Nov 5, 2026)

CEO Ron Lombardi said the cut mainly reflects variability in Clear Eyes production at Pillar5, which is expected to reduce product availability and revenue in the second half, and that the outlook for the rest of the portfolio is unchanged. (Prestige Consumer Healthcare Q2 FY27 release, Nov 5, 2026)

A consensus figure is the average of the models published by the analysts who cover Prestige Consumer Healthcare, collected by a data provider and revised up to the day of the report. A quarter that lands above it says how expectations were set as much as how the business did, and the share price on the day also reflects the guidance and the lines no consensus covers.

The consensus figures on this page are Yahoo Finance's, as pulled on the date shown. Each comes with the number of analysts behind it; the smaller that number, the more one revised estimate can move the average.

The figures below are the ones Prestige Consumer Healthcare's own release and filings put weight on for Q2 fiscal 2027, with the latest reported value for each.

What the quarter means for a holding is a separate question from what it reported. The case for and against owning PBH is on is PBH a buy or a sell?, what analysts expect next is on the PBH forecast, and what the company does is on the Prestige Consumer Healthcare (PBH) stock page.

Every number on this page can be traced to a document Prestige Consumer Healthcare published. Checking one takes a couple of minutes, and it is worth doing before you quote a figure anywhere.

• The results release is the document linked in the source line above. Companies publish it on their investor relations site at the moment results go out, and it carries the headline tables: revenue, operating income, net income and EPS for the quarter and the year-ago quarter.
• The same release is filed with the SEC as Exhibit 99.1 to a Form 8-K under Item 2.02, usually on the day of the report. The SEC copy does not change after the fact, which makes it the safer thing to link when you cite a number.
• The quarterly report (Form 10-Q) follows within a few weeks and carries the full financial statements, the segment note and management's discussion of what changed. The fourth quarter is covered by the annual report (Form 10-K) instead.
• Restated comparisons are flagged in the notes on this page. When a company redraws its segments or changes how it adjusts EPS, it restates the year-ago column, so the year-ago figure in a new release can differ from the one printed a year ago. This page always uses the comparison in the newer release, because that is the like-for-like one.

A walk-through of every line in a release, with what each one tells you, is in how to read an earnings report.